Eyeing to increase its field strength to 2500 within the next five years
New Delhi-based herbal pharma company, Aimil Pharmaceuticals is all set to go global by entering the international markets in the first quarter of 2022.
The company that has already strengthened its presence in the country will be launching its products across United Kingdom, Europe, CIS countries and Africa by expanding its digital as well as offline presence with its presence at drug stores, pharmacies and ethnic Indian stores in these markets.
It is eyeing to increase its field strength to 2500 within the next five years and achieve Rs 1000 crore business in India and internationally as well.
“Currently, the global herbal supplements market has reached a value of $ 6.3 billion and industry reports suggest that the market will grow at a CAGR of 6.8% during 2021-2026. We believe this is the most opportune time to take India’s medical legacy before the world for better global health,” said K.K. Sharma, Chairman and MD, AIMIL Pharmaceuticals.
During the pandemic, Aimil Pharmaceuticals manufactured and promoted Ayush Kwath at larger scale and also based on the customer feedback, it developed and launched its own proprietary product Amynity Plus, a multi system immune defence in the dosage form of liquid and drops.
Taking a step ahead in the coming year, the company will focus on its top 5 brands including Neeri (for UTI and kidney Stone), Neeri KFT (for chronic kidney diseases), BGR-34 (for diabetes), Amlycure DS (for liver health), Amycordial (for PCOD and female wellness) and many others.